Market Overview

Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers

Related HALO
Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion
Mid-Morning Market Update: Markets Open Higher; Dollar Tree Misses Q4 Views

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics (NASDAQ: HALO).

In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer to being able to reap the full commercial potential of its rHuPH20 platform, which is being used to develop subcutaneous (sc) formulations of leading IV drugs for Roche and other partners. This opportunity currently drives Halozyme's valuation, but we contend that the market is ignoring certain key pipeline assets, notably PEGPH20, which is in a Phase II study in pancreatic cancer.”

Halozyme Therapeutics closed on Wednesday at $7.69.

Latest Ratings for HALO

Mar 2016JMP SecuritiesMaintainsMarket Outperform
Feb 2016BarclaysMaintainsOverweight
Feb 2016Canaccord GenuityInitiates Coverage onBuy

View More Analyst Ratings for HALO
View the Latest Analyst Ratings

Posted-In: Edison Investment Research Jason ZhangAnalyst Color Analyst Ratings


Related Articles (HALO)

View Comments and Join the Discussion!